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Background. Increased uncoupling protein-2 (UCP-2) expression has been associated with impaired insulin secretion, whereas
UCP-3 protein levels are decreased in the skeleton muscle of type-2 diabetic subjects. In the present studies we hypothesize an
opposing effect of glucose on the regulation of UCP-2 and UCP-3 in pancreatic islets. Methodology. Dominant negative UCP-2
and wild type UCP-3 adenoviruses were generated, and insulin release by transduced human islets was measured. UCP-2 and
UCP-3 mRNA levels were determined using quantitative PCR. UCP-2 and UCP-3 protein expression was investigated in human
islets cultured in the presence of different glucose concentrations. Human pancreatic sections were analyzed for subcellular
localization of UCP-3 using immunohistochemistry. Principal Findings. Dominant negative UCP-2 expression in human islets
increased insulin secretion compared to control islets (p,0.05). UCP-3 mRNA is expressed in human islets, but the relative
abundance of UCP-2 mRNA was 8.1-fold higher (p,0.05). Immunohistochemical analysis confirmed co-localization of UCP-3
protein with mitochondria in human beta-cells. UCP-2 protein expression in human islets was increased ,2-fold after high
glucose exposure, whereas UCP-3 protein expression was decreased by ,40% (p,0.05). UCP-3 overexpression improved
glucose-stimulated insulin secretion. Conclusions. UCP-2 and UCP-3 may have distinct roles in regulating beta-cell function.
Increased expression of UCP-2 and decreased expression of UCP-3 in humans with chronic hyperglycemia may contribute to
impaired glucose-stimulated insulin secretion. These data imply that mechanisms that suppress UCP-2 or mechanisms that
increase UCP-3 expression and/or function are potential therapeutic targets to offset defects of insulin secretion in humans
with type-2 diabetes.
Citation: Li Y, Maedler K, Shu L, Haataja L (2008) UCP-2 and UCP-3 Proteins Are Differentially Regulated in Pancreatic Beta-Cells. PLoS ONE 3(1): e1397.
doi:10.1371/journal.pone.0001397
INTRODUCTION
Prolonged exposure of islets to high glucose or free fatty acid
concentrations causes attenuated glucose-stimulated insulin secre-
tion (GSIS) [1,2]. A number of explanations have been proposed,
including decreased proinsulin biosynthesis, desensitization to the
glucose signal, depleted insulin stores, chronic oxidative stress and
increased beta-cell apoptosis [2–4]. Furthermore, chronic high
fatty acid concentrations may be beta-cell toxic in the context of
concomitant hyperglycemia, referred to as glucolipotoxicity
[1,2,5]. Glucose oxidation generates NADH and FADH, which
donate electrons to the mitochondrial electron transport chain.
Protons subsequently re-enter the mitochondrial matrix via ATP
synthase to generate ATP. The increase in ATP results in the
closure of the ATP sensitive potassium channels, which in turn
leads to depolarization of the cell membrane and an influx of
ionized calcium thereby triggering insulin secretion [6,7].
Therefore, an attenuated increment in mitochondrial membrane
proton gradient following glucose oxidation would be expected to
attenuate the consequent increment in insulin secretion. One
mechanism that may cause a decrease in the mitochondrial
membrane proton gradient is leakage of protons down this
gradient via uncoupling proteins. To the extent that protons re-
enter beta-cell mitochondria via uncoupling proteins and release
energy in the form of heat, they will be unavailable for ATP
synthase to generate ATP [8].
Five different uncoupling protein isoforms are known and they
have been identified in different tissues. UCP-1 is expressed
predominantly in brown adipose tissue, and it is responsible for
shivering thermogenesis in newborn humans and rodents [9,10].
UCP-2 is ubiquitously expressed, whereas UCP-3 is expressed
preferentially in skeletal muscle, brown adipose tissue and
minimally in heart [11,12]. Both UCP-2 and UCP-3 prevent the
reactive oxygen species formation and therefore protect living cells
against oxidative stress [13,14]. Furthermore, UCP-3 plays a
physiological role in fatty acid metabolism by exporting fatty acids
from the mitochondria [15]. UCP-4 and UCP-5 are expressed
mainly in the nervous system [16].
UCP-2 expression is increased by exposure of rodent islets to
high levels of glucose and free fatty acids [17–21]. Furthermore,
UCP-2 expression is upregulated in islets of wild type ob/ob mice
and rats fed a high-fat diet [22–24]. When ob/ob mice lack a
functional UCP-2 gene or when UCP-2 deficient mice were fed
with a high-fat diet, GSIS was improved when compared with
wild-type mice [22,25,26]. Finally, hyperglycemia-induced mito-
chondrial superoxide activates UCP-2, which subsequently
impairs GSIS [21]. These data imply that UCP-2 (and potentially
other uncoupling proteins) may be important in the regulation of
insulin secretion in health, and may contribute to impaired GSIS
in diabetes. To date there is minimal data available in human
islets. UCP-2 mRNA transcription is increased by high glucose in
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UCP-2 protein levels are increased by 24% in human islets isolated
from diabetic subjects compared to control subjects [28]. The
purpose of the present study was to address the following questions:
(1) Is UCP-2 protein expression in human islets increased by chronic
exposure to high concentrations of glucose, and/or oleic acid? (2)
Does endogenous UCP-2 expression regulate GSIS in human islets?
(3) Is UCP-3 expressed in human islets, and if so, (4) Does high
glucose regulate UCP-3 protein expression? (5) Does UCP-3 over
expression regulate GSIS in human islets?
METHODS
Procurement of human islets and cell culture
Islets from the pancreas of organ donors were obtained through
the Juvenile Diabetes Research Foundation human islet distribu-
tion program. Islets were cultured at RPMI medium containing
10% heat-inactivated FCS, 2 mM Glutamax and 100 U/ml
Penicillin/Streptomycin (described hereafter as complete medium)
supplemented with 5.5 mM glucose in humidified air containing
5% CO2. All tissue culture reagents were from Invitrogen
(Carlsbad, CA).
Generation of human UCP-2 dominant negative
adenovirus
Total RNA was extracted from human islets using a Qiagen
RNeasy kit (Qiagen, Santa Clarita, CA), and Omniscript Reverse
Transcriptase (Qiagen) was used for each RT reaction. PCR was
carried out using Platinium Taq DNA polymerase (Invitrogen) and
UCP-2 primers. The PCR primer sequences for human UCP-2
were 59ATGGTTGGGTTCAAGGCCACAG39 and 59TCAGA-
AGGGAGCCTCTCGGGAAG39. PCR reactions were per-
formed with 2 min initial denaturing step, followed by 35 cycles
of 30 sec at 94uC, 30 sec at 55uC and 1 min at 72uC. PCR
samples were run on a 1.2% agarose gel, and inserted into pGEM-
T Easy vector (Promega, Madison, WI). The sequencing of PCR
fragment confirmed 100% homology with published human UCP-
2 sequence (GenBank Accession number: A94592). As well as
generating a construct with UCP-2 we also generated a dominant
negative UCP-2 construct in order to allow us to establish if the
endogenous UCP-2 protein is active in regulation of insulin
secretion. The rationale here is that as wild type UCP-2 in its
functional form is a dimer, the dominant negative approach allows
examination of a reduction in functional wild type protein [29]. To
generate the dominant negative (dn) mutation, aspartic acid at
position 212 was substituted with asparagine using PCR
mutagenesis. This mutation was originally characterized by Mills
et al., who demonstrated that the expression of UCP-2D212N raises
mitochondrial membrane potential [29]. The entire coding region
of dnUCP-2 was inserted in the pAdTrack-CMV expression
vector [30]. Ad-dnUCP-2 adenovirus was generated using
standard procedures [31]. This adenovirus expresses both
dnUCP-2 and green fluorescent protein (GFP). Ad-GFP was
kindly provided by Dr. C. Rhodes (University of Chigaco, IL)[32].
Transduction of humans islets with dnUCP-2
adenovirus
One hundred islets were transduced with adenovirus expressing
GFP (Ad-GFP) as a control or adenovirus expressing dominant
negative human UCP-2 (Ad-dnUCP-2) at 3610
6 pfu/islet. Islets
were incubated in viral solution at 37uC. After 3 hr, islets were
washed twice in complete medium, and transferred on a 35-mm
suspension culture dish.
Mitochondrial membrane potential detection
Mitochondrial membrane potential was detected by staining living
islets with 5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazolyl-
carbocyanine iodide (JC-1, Molecular Probes, Eugene, OR). JC-1
is a lipophilicdye, which selectively enters into the mitochondriaand
forms red aggregates as the mitochondria membrane becomes more
polarized [33,34]. Isletswerecultured on extracellular matrix-coated
chamberslidesderived fromhuman bladdercarcinomacells (HTB9,
[35]), allowing islets to detach to the slide and spread. Three days
later,isletsweretransducedwithAd-GFPorAd-dn-UCP-2at3610
6
pfu/islet as described above. Forty-four hours after transduction,
medium was replaced with Krebs Ringer buffer (119 mM NaCl,
4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 1.2 mM KH2PO4,
25 mM NaHCO3, 2 mM glucose). Islets were stained with 10 mg/
ml JC-1 for 30 minutes at 37uC and examined with a confocal
microscope (Leica TCS-SP, Leica Microsystems). Total islet area
and mitochondia (red) were measured using Image-Pro Plus 4.1
(Media Cybernetics, Silver Spring, MD).
Insulin release by transduced human islets
Fifteen transduced islets were placed in perifusion chambers and
perifused for 40 min with oxygenated Kreb’s Ringer bicarbonate
buffer, pH 7.4, at basal (4 mM) glucose followed by increased
(16 mM) glucose concentration for 60 min as previously described
in detail [36,37]. Briefly, perfusate was collected at one-minute
intervals and insulin was measured in duplicate every 4 minutes
from 24 to 64 minutes with a two-site insulin immunospecific
ELISA. Four separate human islet donors were used. One
experiment was performed in duplicate (two separate perfusions
per islet batch) and three others in triplicate.
Generation of human UCP-3 adenovirus
The PCR primer sequences for human UCP-3 were 59 ATGG-
TTGGACTGAAGCCTTCAG39 and 59TCAAAACGGTGAT-
TCCCGTAAC39. The sequencing of PCR fragment confirmed
100% homology with published human UCP-3 sequence
(GenBank Accession number: U94592). Primers were used to
generate EcoRI and XhoI sites, the entire coding region of UCP-3
was inserted into pENTR2B (Invitrogen, Carlsbad, CA) and
subsequently into pAd/CMV/DEST adenovirus vector (Invitro-
gen). Recombinant adenoviruses expressing human UCP-3 and
luciferase (control) were generated and purified according to
manufacturer’s instructions (Invitrogen).
Western blot analysis
Total protein samples were prepared in Laemmli sample buffer
from human islets. Twenty mg of protein was separated on a 12%
SDS-PAGE and transferred to PVDF membranes (Bio-Rad,
Hercules, CA). Membranes were blocked with 5% nonfat dry milk
in 0.1% Tween/Tris-buffered saline (TBS-T), and incubated
overnight at 4uC in 2.5% milk in TBS-T containing polyclonal
rabbit anti-UCP-2 (1:1000; RDI-UCP2MabrX, Research Diag-
nostics, Flanders, NJ) or rabbit anti-UCP-3 (1:500; AB-3046,
Chemicon, Temecula, CA). The specificity of this UCP-2 antibody
has been previously documented [38]. To confirm the specificity of
UCP-2 antibody, it was incubated with an excess of UCP-2 control
peptide (10 mg of peptide per 1 mg of antibody; RDI-UCP2M-CP,
Research Diagnostics) for 4 hr before continuing with the
membrane overnight at 4uC. No UCP-2 signal was detected after
this incubation. Furthermore, we used a mouse tissue panel to
confirm the antibody specificity. This analysis demonstrated that
UCP-2 is expressed in mouse spleen and lung, but not in skeletal
muscle, as has been shown previously [39]. We chose to use UCP-3
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previously extensively validated using knock-out mice and
adenoviral overexpression [40–42]. Membranes were washed five
times with TBS-T and incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG (1:3000; Zymed Laboratories, S.
San Francisco, CA) for 1 hr. Proteins were visualized using
enhanced chemiluminescence (ECL; Amersham, UK). Filters were
stripped using Restore Western Blot Stripping buffer (Pierce,
Rockford, IL) and reprobed with anti-b-actin antibodies (1:1000,
Cell Signaling Technology, Beverly, MA). Protein expression levels
were analyzed using the Un-Scan-It program (Silk Scientific,
Orem, UT).
Real-time quantitative PCR
Real-time quantitative PCR analysis was performed on LightCycler
system (Roche Applied Science, Indianapolis, IN) by SYBR Green I
dye detection. The reactions were assembled following the
manufacturer’s recommendation. Briefly, 20 mlo fr e a c t i o nm i x t u r e
contain 1x buffer (LC FastStart DNA Master Plus SYBR green,
Roche), 1 mM forward and reverse primers, and the human islet
cDNA template. The PCR conditions were 10 min at 95uC,
followed by 45 cycles of 2 s at 95uC, 2 s at annealing temperature,
and 12 s at 72uC. We verified the specificity of PCR by measuring
the melting curve of the PCR product at the end of reaction.
Fluorescent data are specified for collection during primer extension.
The relative cDNA ratio was calculated using a-tubulin as a
reference calibrator to normalize equal loading of template cDNA:
59AGAGTCGCGCTGTAAGAAGC39 and 59TGGTCTTGTC-
ACTTGGCATC39. The PCR primer sequences for human UCP-2
were 59TCAATGCCTACAAGACC39 and 59TCTTGACCAC-
GTCTACA39, and for human UCP-3 59TGAAGGTCCGATTT-
CAG39 and 59GATGTCGTAGGTCACCA39.
Immunohistochemistry
Human pancreatic specimens of non-diabetic subjects were
obtained from normal pancreas removed at surgery for pancreatic
adenomas from the Mayo Clinic (Rochester, MN). A pancreatic
specimen that morphologically appeared to be unaffected by the
underlying disease was fixed in formaldehyde and embedded in
paraffin for subsequent staining. Four mM sections were were
deparaffinized in toluene, rehydrated in grades of alcohol, and
washed in H2O. All slides were subject to antigen-retrieval
protocols using antigen unmasking buffer (Vector Laboratories,
Burlingame, CA). After antigen unmasking, the slides were cooled
to room temperature, permeabilized in 0.4% Triton X-100/TBS,
and blocked with 0.2% Tween 20/3% IgG-free bovine serum
albumin (BSA)/TBS. Primary Ab’s were diluted in the blocking
solution at the following dilutions: rabbit anti-UCP3, 1:75
(Chemicon), mouse anti-mitochondria, 1:200 (ab3298, abcam,
Cambridge, MA) and guinea pig anti–insulin 1:500 (Dako,
Carpinteria, CA). Goat-derived secondary Ab’s conjugated to
FITC or Cy3 were diluted 1:200 (Jackson ImmunoResearch
Laboratories, West Grove, PA). To determine the specificity of
UCP-3 antibody, it was incubated with 10-fold excess of UCP-3
control peptide (AG769, Chemicon) for 1 hr before continuing
with immunostaining. All slides were mounted with Vectashield
(Vector Laboratories). Fluorescent slides were viewed using a Leica
DXMRA confocal microscope and images acquired using
Volocity software (Improvision, Lexington, MA).
Glucose-stimulated insulin secretion (GSIS)
For acute insulin release in response to glucose, islets were washed
and preincubated(30 min)inKRB containing 2.8 mMglucose.The
KRB was then replaced by KRB containing 2.8 mM glucose for 1 h
(basal), followed by additional 1 h incubation in KRB containing
16.7 mM glucose. Islets were extracted with 0.18 N HCI in 70%
ethanol for determination of insulin content. Insulin was determined
using a human insulin ELISA kit (Alpco, Windham, NH).
Statistics
Results are presented as means6SE. Statistical calculations were
carried out by student’s t-test using GraphPad Prism (San Diego,
CA). A p-value ,0.05 was taken to indicated a significant difference.
RESULTS
Glucose and fatty acid regulation of UCP-2 protein
expression in human islets
UCP-2 protein expression was increased 2.660.6 (p,0.05) fold in
islets cultured for 24 hr at 11 mM glucose, when compared to
islets cultured at 5.5 mM glucose (Fig. 1A). Insulin release from
human islets increased 461-fold in response to 11 mM glucose
(p,0.05, data not shown). In order to evaluate the effect of free
fatty acids on UCP-2 protein expression in the presence of high
glucose, isolated human islets were cultured for 24 hr in 11 mM
glucose containing medium with or without 0.45 mM oleic acid.
As shown in figure 1B, oleic acid potentiated the effect of high
glucose by increasing UCP-2 expression 1.560.1-fold (p,0.05) in
human islets in the presence of 11 mM glucose when compared to
islets cultured with 11 mM glucose without oleic acid. Insulin
release from human islets increased (1.660.2-fold, p,0.05) in
response to oleic acid (data not shown). We also examined the
effect of 0.45 mM oleic acid on UCP-2 expression at 4 mM
glucose. Under these conditions, oleic acid increased UCP-2
expression by 1.360.1-fold (data not shown).
Effect of dominant negative UCP-2 misexpression on
insulin secretion by human islets
Adenoviral misexpression of dnUCP-2 resulted in an approximate
4-fold increase in UCP-2 protein expression compared to control
human islets (Fig. 2A). Furthermore, adenoviral-mediated increase
in UCP-2 protein expression indicates that this band is indeed
UCP-2. To evaluate whether dnUCP-2 expression alters mito-
chondrial membrane potential, dnUCP-2 and GFP expressing
human islets were stained with a mitochondria-specific voltage-
sensitiveJC-1dye.The intensityofJC-1 red fluorescenceisincreased
as mitochondrial membrane potential is increased [33,34,43]. The
islets that expressed dnUCP-2 had a significant increase in
membrane potential when compared to control islets (Fig. 2B). To
determine the potential for UCP-2 to regulate insulin secretion in
human islets, they were transduced with Ad-dnUCP-2 or Ad-GFP
and perifused (Fig. 2C). The relative increase in insulin secretion in
dnUCP-2 expressing islets compared to GFP expressing islets was
85.6612.7% (p,0.001) at basal glucose (4 mM), whereas during
glucose stimulation (16 mM), the relative increase was 44.268.5%
(p,0.001) in islets expressing dnUCP-2 vs. GFP.
UCP-3 expression in human islets
A single mRNA band of the expected size for UCP-3 was
amplified from human islets (Fig. 3A). The cloning and sequencing
of the PCR fragment confirmed perfect homology with the
published long form of human UCP-3 mRNA sequence (GenBank
Accession number: NM003356). Having identified transcription of
UCP-3 in human islets, we used quantitative PCR in order to
measure the relative abundance of UCP2 and UCP3 mRNA in
human islets. Human islets had 8.161.4-fold more UCP2
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concentrations). We next investigated UCP-3 protein expression in
human islets using western blotting and immunohistochemistry.
UCP-3 protein expression was decreased by 40614% in human
islets cultured at 11 mM glucose, when compared to islets cultured
at 5.5 mM glucose (p,0.05, Fig. 3B). To examine the expression
of UCP-3 in the pancreas, human pancreatic sections were
immunostained with an antibody against the C-terminus of UCP-
3. To test antibody specificity, we blocked the UCP-3 antibody
signal with specific UCP-3 peptide before staining. No positive
staining was observed (data not shown). Next we stained human
pancreatic tissue with UCP-3 and mitochondria antibodies
(Fig. 3C). The beta-cells had a punctuate staining of UCP-3 that
colocalized with mitochondria in beta-cells.
To investigate the effect of UCP-3 overexpression on GSIS, we
prepared UCP-3 adenoviruses. Adenoviral overexpression of
UCP-3 resulted in an approximate 3-fold increase in UCP-3
protein expression compared to control human islets (Fig. 4A).
Forty-eight hr after transduction, we performed GSIS assays in
human islets. No significant changes in insulin secretion were
observed at basal levels at 2.8 mM glucose in UCP-3 expressing
islets compared to control islets. However, as already seen in the
perifusion experiment, dnUCP-2 increased basal insulin secretion
by 1.5-fold compared to untreated control islets (p,0.05).
Stimulated insulin secretion at 16.7 mM glucose was significantly
increased in human islets expressing UCP-3 or dnUCP-2 (1.8- and
2.1-fold, respectively, p,0.05, Fig. 4B) compared to scrambled
control. This resulted in a 37% and 40% increase in the
stimulatory index by UCP-3 and dnUCP-2, respectively in human
islets (p,0.05, Fig. 4C).
DISCUSSION
UCP-2 expression is increased in rodent islets in response to either
chronic high glucose or free fatty acid concentration exposure and
diabetic human islets [17–22,28,44]. This increased UCP-2
expression may contribute to impaired GSIS in type-2 diabetes
[28]. Uncoupling proteins therefore have become an interesting
focus for hyperglycemia mediated impaired insulin secretion.
Figure 1. UCP-2 protein is upregulated by glucose and oleic acid in human islets. A Human islets were cultured at 5.5 or 11 mM glucose for 24 hr.
B Human islets were cultured at 11 mM glucose plus 1% BSA containing medium (control) or supplemented with 0.45 mM oleic acid for 24 hr. Total
protein extracts were analyzed on a Western blot using UCP-2 antibodies. Upper panel, The intensities of the protein signal were quantified by
scanning of images; lower panel, the UCP-2 and b-actin in one representative experiment. All values are mean6SE of at least four independent
experiments from separate human islet donors (t-test; *, p,0.05 relative to control).
doi:10.1371/journal.pone.0001397.g001
Figure 2. Dominant negative UCP-2 enhances insulin secretion in
human islets. A Levels of UCP-2 protein in human islets following
adenoviral misexpression of dn-UCP-2 (+) or GFP (2). B DnUCP-2
increases mitochondrial membrane potential. Human islets grown on
extracellular-matrix-coated slides were transduced with Ad-dnUCP-2 or
Ad-GFP. Mitochondrial membrane potential was detected by live
staining with JC-1, and the JC-1 and islet cell area were measured
using Image-Pro Plus software. Bar graph shows the percentage of JC-1
(area) divided by total islet area (t-test; *, p,0.05 relative to control). C
Human islets were transduced with Ad-dnUCP-2 (&) or Ad-GFP (%,
control) and cultured in suspension at 5.5 mM glucose before
perifusion. Islets were perifused at 4 mM and 16 mM glucose and
insulin concentrations were measured every 4 min. Results are of four
independent experiments using four separate human islet donors. Data
are presented as means6SE and analyzed by t-test, *, p,0.001.
doi:10.1371/journal.pone.0001397.g002
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at 5.5 or 11 mM glucose, and total protein extracts were analyzed on a western blot using UCP-3 antibodies. The intensities of the protein signal were
quantified by scanning of images; blots for UCP-3 and b-actin is shown for one representative experiment. Data are expressed as means6SE, n=3,
* p,0.05. C UCP-3 is expressed in human pancreatic islets, where it colocalizes with mitochondria. A representative layer of human pancreata is
depicted showing UCP-3, mitochondria and overlay. Images were acquired using confocal microscope and imaged at x63 magnification, bar=20 mm.
doi:10.1371/journal.pone.0001397.g003
Figure 4. UCP3 over expression in human islets increases glucose-stimulated insulin secretion. A Western blot analysis of UCP-3 expression in
transduced islets. B Isolated human pancreatic islets were cultured on extracellular matrix-coated dishes and transduced with adenoviruses
expressing control virus (luciferase, Luc), UCP-3 or dnUCP-2. Basal and stimulated insulin secretion indicate the amount secreted during 1-hour
incubations at 2.8 (basal) and 16.7 mM (stimulated) glucose following the 2-day culture period after transduction, normalized to whole islet insulin
content. C Stimulatory index denotes the amount of stimulated divided by the amount of basal insulin secretion. Data represent results of two
different experiments from two different organ donors in quadruplicate. Results are means6SE, *p,0.05 compared to control.
doi:10.1371/journal.pone.0001397.g004
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three-fold in human islets cultured at 22 mM glucose for 24 hr
[27]. We observed a similar increase in UCP-2 protein when cells
were cultured at the presence of 11 mM glucose for 24 hr, glucose
concentration typically present in humans with diabetes. In line
with these data and the concept of glucotoxicity, UCP-2
overexpression impairs b-cell function [45]. This increased
UCP-2 expression in the presence of glucose was further amplified
by 50% by addition of the actively oxidized fatty acid oleic acid to
human islets at a concentration typically present in diabetes
(,0.45 mM). These data are in agreement with the increase of
UCP-2 expression by free fatty acids in isolated rodent islets and in
cultured mouse insulinoma cells [18,20,44,46]. This may also be a
possible underlying mechanism of free fatty acid induced impaired
GSIS in human islets shown during perifusion [47] as well as
during static incubation [48]. Taken together these data suggest
that the chronically increased glucose and fatty acid concentra-
tions typically present in type-2 diabetes would have an additive
effect to increase the expression of UCP-2 protein in islets, an
effect that would be expected to attenuate GSIS. The fact that
both glucose and oleic acid had this effect implies that the
upregulation of UCP-2 protein expression is signaled by traffic
through the tricarboxylic acid cycle or a down stream effect of this.
Having established that UCP-2 is upregulated under conditions
present in type-2 diabetes (high glucose concentrations and free
fatty acid concentrations) we sought to establish if the endogenous
UCP-2 protein expressed in human islets plays a role in insulin
secretion. Rodent studies demonstrated that islets isolated from
UCP-2 knock-out mice, when compared to wild-type islets, secrete
more insulin when cultured in basal and high glucose concentra-
tions [22]. Therefore to establish if the endogenous UCP-2 protein
expressed in human islets regulated insulin secretion we employed
a dominant negative UCP-2 approach in human islets. Using this
approach we report increased insulin secretion in response to basal
as well as high glucose concentrations in isolated perifused human
islets expressing a dominant negative form of UCP-2.
We also report that UCP-3 is expressed in human islets.
Previously, when the PCR method was used to amplify UCP
RNAs in human islets, only UCP-2 RNA was detected [23]. This
first report of UCP-3 expression in human islets poses additional
questions about the potential role of UCPs in the modulation of
insulin secretion in response to glucose. We investigated the
relationship between UCP-2 and UCP-3 mRNA in human islets
and report that the level of UCP-3 mRNA expression in human
islets was only around 10% of that of UCP-2. We also report that
UCP-3 protein is expressed in human pancreatic islets. Chronic
exposure of islets to high glucose concentrations attenuated UCP-3
protein expression, whereas UCP-2 protein levels were increased.
This suggests a different role of UCP-3 on glucose homeostasis.
UCP-3 protein levels were lower in skeletal muscle of prediabetic
(impaired glucose tolerance) and type-2 diabetic subjects com-
pared to healthy control subjects [49,50]. Furthermore, it was
reported that UCP-3 protein level was negatively correlated with
plasma glucose and insulin levels [49]. Moreover, mice overex-
pressing UCP-3 have reduced fasting plasma glucose and insulin
levels indicating improved glucose homeostasis [49,51,52].
Because UCP-3 protein levels were decreased at high glucose
concentrations, we over-expressed UCP-3 in isolated human islets
and measured insulin secretion at basal and increased glucose
concentrations. Interestingly, both UCP-3 overexpression and
UCP-2 depletion resulted in a 1.4-fold increased GSIS index in
isolated human islets. Recent studies demonstrated that modest
overexpression of UCP-3 in muscle cells suppressed reactive
oxygen species (ROS) production and increased fatty acid
oxidation [40]. These results suggest that increased expression of
UCP-3 may be beneficial by preventing harmful ROS production
and protecting mitochondria against fat accumulation by improv-
ing fatty acid metabolism [15,40,53]. Therefore, low UCP-3 levels
may contribute to the pathogenesis of type-2 diabetes [54].
In summary, we report here that UCP-2 protein expression is
increased in response to glucose in human islets, confirming the
corresponding findings made in rodent islets. Moreover, by use of
a dominant negative approach we demonstrate that endogenous
UCP-2 expression in human islets negatively regulates insulin
secretion. We report that UCP-3 is also expressed in human islets,
and its expression is decreased in response to high glucose
concentrations. Finally, we demonstrate that GSIS is increased
human islets over expressing UCP-3. These studies support the
emerging concept that UCP-2 (and possibly UCP-3) expression in
human islets may contribute to decreased GSIS in patients with
type-2 diabetes who are exposed to chronically increased glucose
levels. Moreover, these data imply that UCP-2 and UCP-3 may
have distinct roles in regulating beta-cell function. Increased
expression of UCP-2 in humans with chronic hyperglycemia and/
or increased fatty acid concentrations may contribute to impaired
GSIS. On the other hand, decreased expression of UCP-3 in high
glucose concentrations may impair beta-cell function, implicating
that mechanisms that increase UCP-3 expression and/or function
are potential therapeutic targets to offset defects of insulin
secretion in humans with type-2 diabetes.
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